Top Page
Diaceutics
(LSE:DXRX)
Diaceutics (DXRX) vs. iShares MSCI United Kingdom ETF (EWC)
Diaceutics Business Overview & Revenue Model
Diaceutics Earnings Call Summary
Diaceutics Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 32.16M | 23.70M | 19.50M | 13.94M | 12.70M |
| Gross Profit | 28.27M | 19.71M | 14.04M | 10.57M | 9.33M |
| EBITDA | 2.77M | 2.36M | 3.61M | 2.11M | 178.00K |
| Net Income | -1.70M | -1.75M | 724.00K | 561.00K | 263.00K |
Balance Sheet | |||||
| Total Assets | 48.62M | 46.34M | 48.26M | 45.01M | 43.52M |
| Cash, Cash Equivalents and Short-Term Investments | 12.74M | 16.67M | 19.84M | 19.68M | 25.25M |
| Total Debt | 1.06M | 1.21M | 1.33M | 1.56M | 118.00K |
| Total Liabilities | 8.76M | 5.56M | 5.74M | 4.36M | 3.28M |
| Stockholders Equity | 39.86M | 40.79M | 42.51M | 40.65M | 40.24M |
Cash Flow | |||||
| Free Cash Flow | -3.98M | -3.54M | 278.00K | -5.03M | -6.04M |
| Operating Cash Flow | 651.00K | 1.31M | 5.15M | 570.00K | 253.00K |
| Investing Cash Flow | -4.03M | -4.21M | -4.87M | -5.60M | -6.29M |
| Financing Cash Flow | -64.00K | -239.00K | -132.00K | -270.00K | 19.61M |
Diaceutics Technical Analysis
Diaceutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $116.19M | ― | -4.18% | ― | 35.69% | 2.42% | |
66 Neutral | £131.14M | 22.25 | 8.95% | 4.80% | -4.59% | 165.38% | |
51 Neutral | $7.86B | -0.33 | -41.57% | 2.23% | 23.26% | -2.03% | |
49 Neutral | £20.96M | ― | -68.75% | ― | 30.92% | 36.40% | |
48 Neutral | £246.95M | ― | -73.02% | ― | ― | ― | |
46 Neutral | £107.93M | ― | 167.16% | ― | -100.00% | -23.91% | |
45 Neutral | £7.95M | ― | -130.73% | ― | 226.45% | 53.51% |
Diaceutics Corporate Events
Diaceutics PLC announced its participation in the Canaccord Genuity 45th Annual Growth Conference, highlighting its role as a prominent player in the pharma and biotech sectors. This event presents an opportunity for Diaceutics to engage with global investors and showcase its innovative solutions, potentially enhancing its market positioning and stakeholder engagement.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC has announced the purchase of ordinary shares by trustees on behalf of key personnel as part of its UK and Global Share Incentive Plan. The company has matched these purchases with a 1:1 share award, reflecting its commitment to employee incentives and aligning interests with stakeholders. This move is part of a broader strategy to facilitate share trading and enhance transparency in shareholding, with implications for shareholder notifications under regulatory guidelines.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC has appointed Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. With her extensive legal experience in the pharmaceutical sector, including roles at Sandoz and Novartis, DeWitt is expected to significantly contribute to Diaceutics’ strategic growth and legal functions. Her expertise in litigation, regulatory, and transactional legal functions aligns with the company’s growth ambitions, positioning Diaceutics to enhance its leadership team and support its mission in precision medicine.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC has announced the issuance of 1,886,357 share options to its directors, senior management, and key staff as part of its Employee Share Option Plan. This move is aligned with the company’s long-term incentive plan, aiming to enhance performance through specific criteria such as Total Shareholder Return, revenue growth, and EBITDA margin. The share options, which represent approximately 7.32% of the company’s current issued share capital, are set to vest over a three-year period, reflecting Diaceutics’ commitment to aligning employee incentives with company performance and shareholder interests.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC reported a strong performance in the first half of 2025, with a 22% revenue growth on a constant currency basis, reaching £14.6 million. The company has demonstrated significant commercial momentum, with a 16% increase in annual recurring revenue and a strong order book of £29.4 million. Diaceutics continues to expand its customer base, working with 74 therapeutic brands across 43 customers, including 18 of the top 20 global pharma companies. The company remains debt-free with £10.4 million in cash, supporting ongoing investment in product innovation and commercial growth. The outlook for the second half of 2025 is positive, with expectations for continued margin improvement and market expansion beyond precision medicine.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £185.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC has announced the expansion of its PMx commercialization partnership contract following early success, reflecting their partner’s confidence in the solution. This expanded agreement is expected to contribute to incremental service revenue in FY2025 and strengthens Diaceutics’ position in the precision medicine ecosystem. The new contract introduces Signal Connect, a service designed to enhance healthcare professionals’ awareness and clinical actionability, particularly in cases involving rare or novel biomarkers. The PMx solution continues to demonstrate its value by enabling cost-effective, agile launches and maximizing patient discovery for biopharma companies.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £185.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC has announced the expansion of its PMx commercialization partnership contract, following early success in the collaboration. This expansion is expected to increase service revenue in FY2025 and solidify Diaceutics’ role as a strategic partner in the precision medicine ecosystem. The enhanced contract introduces Signal Connect, a service aimed at supporting healthcare professionals in identifying and acting on rare or novel biomarkers, thus facilitating access to targeted therapies. The PMx solution continues to offer a cost-effective commercialization strategy for biopharma companies, enabling efficient launches and maximizing patient discovery.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £185.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC announced that its trustees have purchased ordinary shares on behalf of key personnel as part of the company’s Share Incentive Plan (SIP) schemes. The company has matched these purchases with a 1:1 share award, and the shares will be held by the trust until they vest according to the scheme rules. This move is part of a broader strategy to facilitate employee participation in the company’s growth, potentially enhancing stakeholder alignment and motivation.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC announced that all resolutions proposed at its Annual General Meeting were passed, reflecting strong shareholder support. The resolutions included re-electing directors, appointing auditors, and authorizing share allotments, indicating stable governance and strategic alignment with shareholder interests.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC has announced that trustees of its 2020 Employee Benefit Trust have purchased ordinary shares on behalf of key personnel under the company’s Share Incentive Plan. The company has matched these purchases with a 1:1 share award, utilizing unallocated shares previously issued. This move is part of a broader strategy to facilitate share trading and incentivize employees, potentially impacting shareholder calculations under FCA rules.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £195.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC has announced the posting of its Annual Report for the year ended 31 December 2024, along with the Notice of the 2025 Annual General Meeting (AGM) to shareholders. The AGM is scheduled for 18 June 2025 in Belfast, and the documents will be accessible on the company’s website, indicating a transparent approach to stakeholder engagement and corporate governance.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC announced that Delia Keeling, closely associated with the company’s Chair, Peter Keeling, sold 500,000 ordinary shares at 126 pence each. This transaction reduces the Keelings’ combined shareholding to approximately 17.98% of the company’s issued share capital. This sale is significant as it reflects a change in the major holdings of the company, potentially impacting its market perception and shareholder dynamics.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Diaceutics PLC reported strong financial and commercial performance for FY 2024, with a 39% revenue growth to £32.2 million and a 50% increase in adjusted EBITDA to £4.2 million. The company expanded its sales presence in the US and launched its PMx solution, contributing to its growth momentum. With an order book of £24.9 million and an ARR of £16.8 million, Diaceutics is positioned for continued growth in 2025. The company secured three new enterprise-wide engagements and increased its customer base, working with 18 of the top 20 global pharma companies. Despite macroeconomic uncertainties, Diaceutics remains confident in achieving its growth and profitability targets for 2025.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.